JPM 2026 | 营收跳涨70%后，布鲁克CEO抛出全新战略目标

Core Insights - The article highlights Brook's strategic shift towards refined operations, focusing on profit margins and EPS growth, alongside a significant annual cost reduction plan of $120 million [1][3][2]. Strategic Shift - Brook has transitioned from an aggressive acquisition strategy to a focus on operational efficiency, marking a pause in its expansion efforts after achieving a 12% compound annual growth rate over the past five years [3]. - The new strategy, dubbed Project Accelerate 3.0 (PA3), emphasizes maximizing operational efficiency rather than merely pursuing revenue growth [3]. Market Implications - This strategic pivot signals a more resilient pricing strategy in the high-end market, indicating a shift in global competition from mere parameter comparisons to comprehensive performance evaluations [5]. Technological Innovations - Brook is betting on the "post-genomics era," focusing on proteomics and spatial biology, with the launch of two significant products: CosMx WTX for spatial biology and the timsOmni mass spectrometry platform for top-down proteomics [7]. - CosMx WTX integrates NanoString technology to cover over 18,000 RNA targets, enhancing pathological research capabilities [7]. - The timsOmni platform represents a milestone in protein analysis, transitioning from piecemeal approaches to comprehensive profiling [7]. Additional Business Segments - Brook is also capitalizing on two lucrative segments: semiconductor technology and automated AI laboratories, which have contributed over $300 million in revenue with high profit margins [8]. - The semiconductor segment is driven by the demand for X-ray and atomic force microscopy (AFM) in chip manufacturing, while the automated AI laboratory initiative promotes a vision of "unmanned laboratories" to global pharmaceutical companies [8].